Abstract 872P
Background
Intratumor heterogeneity (ITH) is a major cause of treatment failure in cancer. Data on ITH are scarce in head and neck squamous cell carcinoma (HNSCC). We evaluated pathological ITH (pITH) and assessed its prognostic value, along with classical prognostic parameters.
Methods
HNSCC patients treated with curative-intent primary surgery from SCANDARE (NCT03017573) were included. A pITH score (I, II, III-low and III-high) was assessed on biopsies, according to the relative contribution of poorly- and well-differentiated tumor contingents. Univariate and multivariate prognostic Cox models of recurrence-free survival (RFS) were made on pITH score and clinical (age, sex, smoking history, alcohol consumption, AJCC T- and N-stage, HPV status), pathological (differentiation, tumor-infiltrating lymphocytes [TILs], and PD-L1 combined positive score (CPS) features. We tested associations between pITH score and these parameters.
Results
A total of 88 patients were included. Most frequently tumor locations were oral cavity (51%). Most patients had low T-stage (T1-2, 59%) and HPV-negative tumor (74%). Ten patients (11%) had a I/II ITH score, 49 (56%) a III-low and 29 (33%) a III-high. Median follow-up was 17 months and median RFS was 18 months (95% CI, 14-40). In univariate analysis, the pITH score did not correlate with RFS (P = 0.6). T-stage, N-stage and TILs enrichment were associated with RFS (T3-4 vs T1-2, HR = 2.7, 95% CI, 1.4-5.3; N1-2 vs N0, HR = 1.9, 95% CI, 1.0-3.7; TILs ≥10% vs TILs <10%, HR = 0.3, 95% CI, 0.1-0.8). We found that low T-stage (T1-2) and high TILs enrichment (TILs ≥10%) were associated with a reduced risk of relapse in multivariate analysis (HR = 0.4, 95% CI, 0.2-0.9 and HR = 0.2, 95% CI, 0.04-0.5, respectively). In comparison with non-smokers, smokers had a higher proportion of tumors with I-II ITH score (19% vs 3%) and a lower proportion of tumors with III-low ITH score (48% vs 65%, adjusted P = 0.05).
Conclusions
We reported an association between pITH score and smoking history. pITH score was not found to be prognostic whereas TILs enrichment ≥10% was associated with a favorable prognosis in patients with HNSCC treated with upfront surgery. This finding is to be confirmed in an independent population.
Clinical trial identification
NCT03017573 SCANDARE.
Editorial acknowledgement
Legal entity responsible for the study
Pr Christophe Le Tourneau.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12
930P - Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Presenter: Marcelo Bonomi
Session: Poster session 12
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12